Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

ClinicalTrials.gov ID: NCT02049905

Public ClinicalTrials.gov record NCT02049905. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.

Study identification

NCT ID
NCT02049905
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
ImmunityBio, Inc.
Industry
Enrollment
433 participants

Conditions and interventions

Eligibility (public fields only)

Age range
15 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2014 (Type not available)
Primary completion
May 2017 (Actual)
Completion
May 2017 (Actual)
Last update posted
Jun 13, 2024

2014 – 2017

United States locations

U.S. sites
36
U.S. states
21
U.S. cities
33
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35243 —
Arizona Oncology Associates, PC Phoenix Arizona 85016 —
The University of Arizona Tucson Arizona 85719 —
City of Hope Medical Group Duarte California 91010 —
Samuel Oschin Cancer Center Los Angeles California 90048 —
UCLA Medical Center Los Angeles California 90095 —
Sarcoma Oncology Center Santa Monica California 940403 —
Stanford University Medical Center Stanford California 94305 —
U of CO Health Sciences Center Aurora Colorado 80045 —
Rocky Mountain Cancer Centers Denver Colorado 80218 —
Mayo Clinic Jacksonville Florida 32224 —
Moffitt Cancer Center Tampa Florida 33612 —
Georgia Cancer Specialists Atlanta Georgia 30341 —
Northwestern Medical Faculty Foundation Chicago Illinois 60611 —
Edward Cancer Center Naperville Illinois 60540 —
Oncology Specialists, SC Niles Illinois 60714 —
Kansas City Cancer Center Overland Park Kansas 66210 —
Massachusetts General Hospital Boston Massachusetts 02114 —
Dana Farber Cancer Institute Boston Massachusetts 02115 —
University of Michigan Ann Arbor Michigan 48109 —
University of Minnesota Minneapolis Minnesota 55455 —
Mayo Clinic Rochester Minnesota 55905 —
Washington University St Louis Missouri 63110 —
Nebraska Methodist Hospital Omaha Nebraska 68114 —
Roswell Park Cancer Institute Buffalo New York 14263 —
Levine Cancer Institute Charlotte North Carolina 28204 —
Wake Forest University Baptist Medical Center Winston-Salem North Carolina 27157 —
University Hospitals Case Medical Center Cleveland Ohio 44106 —
Cleveland Clinic Cleveland Ohio 44195 —
The James Cancer Hospital and Solove Research Institute Columbus Ohio 43202 —
Center for Health and Healing Portland Oregon 97239 —
Jefferson Medical College Philadelphia Pennsylvania 19107 —
U of Pittsburgh Cancer Institute Pittsburgh Pennsylvania 15232 —
Vanderbilt University Nashville Tennessee 37212 —
Fletcher Allen Health Care Burlington Vermont 05405 —
Medical College of Wisconsin Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02049905, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 13, 2024 · Synced Oct 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02049905 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →